| 4.94 -0.04 (-0.8%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.34 | 1-year : | 7.11 |
| Resists | First : | 5.42 | Second : | 6.09 |
| Pivot price | 5.1  |
|||
| Supports | First : | 4.36 | Second : | 3.62 |
| MAs | MA(5) : | 4.95 |
MA(20) : | 5.11 |
| MA(100) : | 7.79 |
MA(250) : | 10.74 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 21.5 |
D(3) : | 21.9 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 19.35 | Low : | 3.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ATOS ] has closed above bottom band by 36.3%. Bollinger Bands are 56.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5 - 5.03 | 5.03 - 5.05 |
| Low: | 4.72 - 4.76 | 4.76 - 4.79 |
| Close: | 4.88 - 4.94 | 4.94 - 4.99 |
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Sun, 12 Apr 2026
Atossa Therapeutics (ATOS) price target decreased by 31.37% to 44.62 - MSN
Fri, 10 Apr 2026
ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Wed, 25 Mar 2026
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update - PR Newswire
Thu, 19 Mar 2026
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives - PR Newswire
Thu, 12 Mar 2026
Atossa test drug boosts muscle strength in Duchenne muscular dystrophy mice - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 21.4 (%) |
| Shares Short | 320 (K) |
| Shares Short P.Month | 409 (K) |
| EPS | -4.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.5 % |
| Return on Equity (ttm) | -62.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -1.23 |
| PEG Ratio | 0 |
| Price to Book value | 1.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|